Shares of Axovant Sciences Ltd. (NYSE:AXON) have earned a consensus rating of “Buy” from the nine ratings firms that are presently covering the company. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $27.50.

Several equities analysts have weighed in on AXON shares. Zacks Investment Research lowered Axovant Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, August 9th. Piper Jaffray Cos. set a $32.00 price objective on Axovant Sciences and gave the company a “buy” rating in a report on Friday, September 23rd. Evercore ISI reaffirmed a “buy” rating and issued a $29.00 price target on shares of Axovant Sciences in a report on Friday, September 23rd. Jefferies Group reaffirmed a “buy” rating and issued a $31.00 price target on shares of Axovant Sciences in a report on Monday, September 26th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Axovant Sciences in a report on Thursday, June 30th.

Axovant Sciences (NYSE:AXON) traded down 2.25% during trading on Friday, hitting $13.01. The stock had a trading volume of 200,979 shares. Axovant Sciences has a 52 week low of $8.86 and a 52 week high of $21.30. The company has a 50-day moving average of $15.30 and a 200-day moving average of $13.67. The stock’s market capitalization is $1.29 billion.

Axovant Sciences (NYSE:AXON) last announced its quarterly earnings data on Monday, August 15th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.02. On average, equities analysts expect that Axovant Sciences will post ($1.68) earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the stock. GSA Capital Partners LLP acquired a new stake in Axovant Sciences during the second quarter valued at about $128,000. Royal Bank of Canada raised its stake in Axovant Sciences by 467.6% in the second quarter. Royal Bank of Canada now owns 10,500 shares of the company’s stock valued at $135,000 after buying an additional 8,650 shares in the last quarter. American International Group Inc. raised its stake in Axovant Sciences by 61.4% in the second quarter. American International Group Inc. now owns 14,070 shares of the company’s stock valued at $181,000 after buying an additional 5,353 shares in the last quarter. Woodstock Corp acquired a new stake in Axovant Sciences during the second quarter valued at about $243,000. Finally, Rhumbline Advisers raised its stake in Axovant Sciences by 61.7% in the second quarter. Rhumbline Advisers now owns 21,471 shares of the company’s stock valued at $276,000 after buying an additional 8,196 shares in the last quarter. 29.45% of the stock is owned by institutional investors.

About Axovant Sciences

Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

5 Day Chart for NYSE:AXON

Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.